Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 48

Results For "EMA"

2776 News Found

Corbion and Kuehnle join forces to develop natural Astaxanthin from algae fermentation
Biotech | August 23, 2025

Corbion and Kuehnle join forces to develop natural Astaxanthin from algae fermentation

Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms


Star Health Insurance settles claims of Rs.11,500 Cr
News | August 23, 2025

Star Health Insurance settles claims of Rs.11,500 Cr

The company has improved access to quality healthcare for seniors across both urban and rural areas


Piramal Pharma Solutions opens dedicated OSD production capabilities at Sellersville, Pennsylvania site
News | August 22, 2025

Piramal Pharma Solutions opens dedicated OSD production capabilities at Sellersville, Pennsylvania site

The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities


HGM acquires Aideo Technologies for Rs. 14 crore to strengthen AI-powered healthcare services platform
Digitisation | August 21, 2025

HGM acquires Aideo Technologies for Rs. 14 crore to strengthen AI-powered healthcare services platform

This acquisition expands HGM's healthcare platform capabilities in revenue cycle management


SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction
Healthcare | August 21, 2025

SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction

The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries


Novo Nordisk's Wegovy approved in the US for the treatment of MASH
News | August 19, 2025

Novo Nordisk's Wegovy approved in the US for the treatment of MASH

The accelerated approval is supported by results from part 1 of the ESSENCE trial


BioAge Labs doses first patient in BGE-102 phase 1 trial
Biotech | August 19, 2025

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants


Pfizer’s sickle cell disease candidate fails Phase III trial
News | August 19, 2025

Pfizer’s sickle cell disease candidate fails Phase III trial

Inclacumab was generally well tolerated in THRIVE-131


Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico
News | August 18, 2025

Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico

The projected business potential is around US$ 1 million in the first year